Détail - canceropole-wordpress

Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic.

Metzger C, Leroy T, Bochnakian A, Jeulin H, Gegout-Petit A, Legrand K, Schvoerer E, Guillemin F

PLoS One. 2023 04 19;18(4):e0269104

Risk of SARS-CoV-2 Infection in Nursing Home Residents According to COVID History and IgG Anti-Spike Antibody Levels.

Jeulin H, Labat C, Benetos A

J Am Med Dir Assoc. 2022 11 11;:

SARS-CoV-2 Variability in Patients and Wastewaters-Potential Immuno-Modulation during the Shift from Delta to Omicron.

Chaqroun A, Hartard C, Josse T, Taverniers A, Jeulin H, Gantzer C, Murray JM, Obepine Consortium,Bertrand I, Schvoerer E

Biomedicines. 2022 08 25;10(9):

SARS-CoV-2 seroprevalence in healthcare workers and risk factors.

Weber S, Didelot A, Agrinier N, Peyrin-Biroulet L, Schvoerer E, Rabaud C, Jeulin H

Infect Dis Health. 2022 05 17;:

Anti-spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents.

Jeulin H, Labat C, Duarte K, Toupance S, Nadin G, Craus D, Georgiopoulos I, Gantois I, Goehringer F, Benetos A

J Am Geriatr Soc. 2022 Apr 29;:

Evaluation of a Lateral Flow Immunoassay COVIDTECH SARS-CoV-2 IgM/IgG Antibody Rapid Test.

Exinger J, Hartard C, Lafferrière F, Fenninger C, Charbonnière LJ, Jeulin H

Jpn J Infect Dis. 2021 Dec 28;:

Performance evaluation of an automated SARS-CoV-2 Ag test for the diagnosis of COVID-19 infection on nasopharyngeal swabs.

Hartard C, Berger S, Josse T, Schvoerer E, Jeulin H

Clin Chem Lab Med. 2021 Jul 30;:

[How genetic variability of hepatitis E virus (VHE) may impact its clinical relevance and transmission].

Hartard C, Jeulin H, Schvoerer E

Virologie (Montrouge). 2021 Jul 29;:

SARS-CoV-2 seroprevalence among Laboratory staff: Safe handling of COVID-19 samples.

Hartard C, Agrinier N, Franck P, Prin-Mathieu C, Debourgogne A, Venard V, Schvoerer E, Jeulin H

Infect Control Hosp Epidemiol. 2021 Jul 21;:1-7

Somatic coliphages are conservative indicators of SARS-CoV-2 inactivation during heat and alkaline pH treatments.

Varbanov M, Bertrand I, Philippot S, Retourney C, Gardette M, Hartard C, Jeulin H, Duval RE, Loret JF, Schvoerer E, Gantzer C

Sci Total Environ. 2021 Jul 15;797:149112

Full-length genome sequencing of RNA viruses-How the approach can enlighten us on hepatitis C and hepatitis E viruses.

Laugel E, Hartard C, Jeulin H, Berger S, Venard V, Bronowicki JP, Schvoerer E

Rev Med Virol. 2021 Jul;31(4):e2197

Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.

Marcelin AG, Charpentier C, Bellecave P, Abdi B, Chaix ML, Ferre V, Raymond S, Fofana D, Bocket L, Mirand A, Le Guillou-Guillemette H, Montes B, Amiel C, Pallier C, Fafi-Kremer S, De Monte A, Alessandri-Gradt E, Scholtes C, Maillard A, Jeulin H, Bouvier-Alias M, Roussel C, Dos Santos G, Signori-Schmuck A, Dina J, Vallet S, Stefic K, Soulié C, Calvez V, Descamps D, Flandre P,

J Antimicrob Chemother. 2021 Jun 7;:

Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.

Gégout Petit A, Jeulin H, Legrand K, Jay N, Bochnakian A, Vallois P, Schvoerer E, Guillemin F

Viruses. 2021 Jun 4;13(6):

Variability in molecular characteristics of Hepatitis E Virus quasispecies could modify viral surface properties and transmission.

Hartard C, Fenaux H, Gentilhomme A, Murray JM, Akand E, Laugel E, Berger S, Maul A, de Rougemont A, Jeulin H, Remen T, Bensenane M, Bronowicki JP, Gantzer C, Bertrand I, Schvoerer E

J Viral Hepat. 2021 Apr 20;:

Epidemiological surveillance of SARS-CoV-2 by genome quantification in wastewater applied to a city in the northeast of France: Comparison of ultrafiltration- and protein precipitation-based methods.

Bertrand I, Challant J, Jeulin H, Hartard C, Mathieu L, Lopez S, ,Schvoerer E, Courtois S, Gantzer C

Int J Hyg Environ Health. 2021 Jan 31;233:113692

Signs of tracheobronchitis may constitute the principal finding on the lung SPECT/CT images of COVID-19 patients.

Bahloul A, Verger A, Mandry D, Jeulin H, Goehringer F, Karcher G, Imbert L, Marie PY

Eur J Nucl Med Mol Imaging. 2021 Jan 8;:

CT abnormalities evocative of lung infection are associated with lower F-FDG uptake in confirmed COVID-19 patients.

Bahloul A, Boursier C, Jeulin H, Imbert L, Mandry D, Karcher G, Marie PY, Verger A

Eur. J. Nucl. Med. Mol. Imaging. 2020 Aug 18;:

Changes in characteristics and management among patients with ST-elevation myocardial infarction due to COVID-19 infection.

Popovic B, Varlot J, Metzdorf PA, Jeulin H, Goehringer F, Camenzind E

Catheter Cardiovasc Interv. 2020 Jul 15;:

Treatment as prevention enrolling at least 75% of individuals on ART will be needed to significantly reduce HIV prevalence in a HIV cohort.

Jeulin H, Jeanmaire E, Murray JM, Malve B, André M, Melliez H, Lanoix JP, Hustache-Mathieu L, Partisani M, Goehringer F, May T, Schvoerer E

J. Clin. Virol.. 2019 Aug 24;120:27-32

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.

Marcelin AG, Grude M, Charpentier C, Bellecave P, Le Guen L, Pallier C, Raymond S, Mirand A, Bocket L, Fofana DB, Delaugerre C, Nguyen T, Montès B, Jeulin H, Mourez T, Fafi-Kremer S, Amiel C, Roussel C, Dina J, Trabaud MA, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Maillard A, Ferre V, Descamps D, Calvez V, Flandre P,

J. Antimicrob. Chemother.. 2019 Feb 20;:

Molecular features of Hepatitis E Virus circulation in environmental and human samples.

Fenaux H, Chassaing M, Berger S, Jeulin H, Gentilhomme A, Bensenane M, Bronowicki JP, Gantzer C, Bertrand I, Schvoerer E

J. Clin. Virol.. 2018 Apr 5;103:63-70

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.

Oussalah A, Avogbe PH, Guyot E, Chery C, Guéant-Rodriguez RM, Ganne-Carrié N, Cobat A, Moradpour D, Nalpas B, Negro F, Poynard T, Pol S, Bochud PY, Abel L, Jeulin H, Schvoerer E, Chabi N, Amouzou E, Sanni A, Barraud H, Rouyer P, Josse T, Goffinet L, Jouve JL, Minello A, Bonithon-Kopp C, Thiefin G, Di Martino V, Doffoël M, Richou C, Raab JJ, Hillon P, Bronowicki JP, Guéant JL,

Oncotarget. 2017 Sep;8(38):62842-62857

The variability of hepatitis B envelope is associated with HBs antigen persistence in either chronic or acute HBV genotype A infection.

Eschlimann M, Malvé B, Velay A, Fenaux H, Berger S, Frippiat JP, Zoulim F, Bensenane M, Bronowicki JP, Goehringer F, May T, Jeulin H, Schvoerer E

J. Clin. Virol.. 2017 Aug;94:115-122

Impact of deletions and mutations in Hepatitis B virus envelope proteins on serological profile and clinical evolution.

Malve B, Eschlimann M, Galgey S, Fenaux H, Zoulim F, Goehringer F, Rabaud C, May T, Jeulin H, Schvoerer E

Virus Res.. 2017 Jun;:

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.

Soulie C, Grudé M, Descamps D, Amiel C, Morand-Joubert L, Raymond S, Pallier C, Bellecave P, Reigadas S, Trabaud MA, Delaugerre C, Montes B, Barin F, Ferré V, Jeulin H, Alloui C, Yerly S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG,

J. Antimicrob. Chemother.. 2017 May;:

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.

Qian C, Campidelli A, Wang Y, Cai H, Venard V, Jeulin H, Dalle JH, Pochon C, D'aveni M, Bruno B, Paillard C, Vigouroux S, Jubert C, Ceballos P, Marie-Cardine A, Galambrun C, Cholle C, Clerc Urmes I, Petitpain N, De Carvalho Bittencourt M, Decot V, Reppel L, Salmon A, Clement L, Bensoussan D

J Hematol Oncol. 2017 May;10(1):102

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.

Oussalah A, Avogbe PH, Guyot E, Chery C, Guéant-Rodriguez RM, Ganne-Carrié N, Cobat A, Moradpour D, Nalpas B, Negro F, Poynard T, Pol S, Bochud PY, Abel L, Jeulin H, Schvoerer E, Chabi N, Amouzou E, Sanni A, Barraud H, Rouyer P, Josse T, Goffinet L, Jouve JL, Minello A, Bonithon-Kopp C, Thiefin G, Di Martino V, Doffoël M, Richou C, Raab JJ, Hillon P, Bronowicki JP, Guéant JL, Study Group FT

Oncotarget. 2016 Aug;:

Herpes simplex virus type 1 hepatitis due to primary infection in a pancreas-kidney transplant recipient.

Feugeas J, Mory S, Jeulin H, Velay A, Pertek JP, Ladriere M, Losser MR

J. Clin. Virol.. 2016 Jul;80:57-9

Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.

Velay A, Jeulin H, Eschlimann M, Malvé B, Goehringer F, Bensenane M, Frippiat JP, Abraham P, Ismail AM, Murray JM, Combet C, Zoulim F, Bronowicki JP, Schvoerer E

J. Viral Hepat.. 2016 May;23(5):387-98

Evaluation of Virological Microparticle Enzyme Immunoassay According to the ISO 15189: Real-Life Experience in a University Hospital.

Lafontaine S, Prin-Mathieu C, Velay A, Agulles O, Schvoerer E, Jeulin H

Clin. Lab.. 2016 ;62(3):275-84

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

Soulie C, Descamps D, Grude M, Schneider V, Trabaud MA, Morand-Joubert L, Delaugerre C, Montes B, Barin F, Ferre V, Raymond S, Jeulin H, Alloui C, Yerly S, Pallier C, Reigadas S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haim-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG

J Antimicrob Chemother. 2015 Feb;70(2):566-72

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.

Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud M, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montes B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin A

J Antimicrob Chemother. 2015 Jan 3. pii: dku535.

Real-life rilpivirine resistance and potential emergence of an E138A-positive HIV strain in north-eastern France.

Jeulin H, Foissac M, Boyer L, Agrinier N, Perrier P, Kennel A, Velay A, Goehringer F, Henard S, Rabaud C, May T, Schvoerer E

J Antimicrob Chemother. 2014 Nov;69(11):3095-102

Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.

Wang Y, Aissi-Rothe L, Virion JM, De Carvalho Bittencourt M, Ulas N, Audonnet S, Salmon A, Clement L, Venard V, Jeulin H, Stoltz JF, Decot V, Bensoussan D

Cytotherapy. 2014 Jan;16(1):122-34